Benefits
59% anxiety reduction and 66% cortisol reduction at low dose
A 60-day double-blind RCT in adults with generalized anxiety (HAMA score >20) confirmed Shoden® at just 60 mg/day reduced anxiety by 59% (Hamilton Anxiety Rating Scale) and lowered morning cortisol by 66–67% vs. placebo's 2.2% change. These outcomes at 60 mg — a quarter of typical ashwagandha doses — reflect Shoden®'s superior withanolide glycoside potency achieved through its patented 35% standardization.
Superior bioavailability vs. other ashwagandha extracts
A crossover bioavailability study in healthy volunteers directly comparing four commercial ashwagandha extracts found Shoden® (35% withanolide glycosides) demonstrated the highest plasma withanolide concentrations and longest duration of action, suggesting Shoden® may be among the more bioavailable commercial ashwagandha extracts (based on a single open-label, manufacturer-associated crossover study that is not independently confirmed). The superior absorption is attributed to withanolide glycosides' enhanced water solubility vs. aglycone withanolides in other extracts.
Sleep quality improvement
Direct sleep evidence for Shoden® specifically is limited: the cited support comes from an animal/in-vitro model and from a randomized trial of a different, non-Shoden ashwagandha extract. Generic ashwagandha extracts have been associated with improvements in sleep quality, sleep latency (time to fall asleep), and morning restfulness — outcomes attributed to cortisol normalization reducing the hypothalamic arousal that impairs sleep onset, and direct GABAergic enhancement that promotes inhibitory neurological tone for sleep.
Testosterone support in men
Testosterone increases in men have been reported in a separate study of Shoden® in aging males (not the cited stress-reduction trial, and not yet independently confirmed) vs. placebo — consistent with the well-established inverse relationship between cortisol and testosterone. By normalizing HPA axis activity and reducing cortisol, Shoden® allows testicular testosterone production to recover from the suppression of chronic stress.
Mechanism of action
HPA axis normalization via withanolide glycoside GABA-A and glucocorticoid receptor modulation
Shoden®'s withanolide glycosides modulate GABA-A receptor sensitivity in the hypothalamus and amygdala — enhancing inhibitory GABAergic tone that normalizes HPA axis overactivation and reduces cortisol secretion. Simultaneously, withanolides act as glucocorticoid receptor modulators — enhancing glucocorticoid feedback sensitivity so that normal cortisol levels more effectively suppress further cortisol secretion. The withanolide glycoside form in Shoden® provides superior water solubility and bioavailability vs. free withanolide aglycones, explaining the clinical efficacy at doses 4–7× lower than standard extracts.
Clinical trials
Randomized, double-blind, placebo-controlled parallel-arm study of Shoden® at 60 mg and 120 mg/day in 60 adults with elevated stress and anxiety (HAMA score >20). 60-day study. Published in Heliyon (2024).
60 adults with generalized anxiety (HAMA >20, morning cortisol >25 mcg/dL). 60-day clinical trial.
Shoden® at 60 mg/day: 59% reduction in HAMA anxiety score vs. placebo. Morning cortisol reduced 66% (60 mg) and 67% (120 mg) vs. 2.2% placebo change. Testosterone was not an outcome of this stress/anxiety trial; Shoden® testosterone findings come from a separate, uncited study in aging males. Well-tolerated at both doses. Confirms clinical efficacy at quarter of typical ashwagandha doses.
Randomized, open-label, crossover comparative bioavailability study of four commercial ashwagandha extracts in 16 healthy volunteers. Published in Current Therapeutic Research.
16 healthy volunteers. Crossover pharmacokinetic study.
Shoden® (35% withanolide glycosides) demonstrated the highest plasma withanolide concentrations and longest duration vs. all other tested commercial extracts (2.5–5% withanolide standardization). First human evidence that withanolide glycosides specifically drive superior ashwagandha bioavailability.